Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $535
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $500 to $535.
August 02, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $500 to $535.
The raised price target and maintained Overweight rating from a reputable analyst are likely to positively impact Vertex Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100